Annual EBITDA
$336.70 M
+$100.10 M+42.31%
31 December 2023
Summary:
Neurocrine Biosciences annual earnings before interest, taxes, depreciation & amortization is currently $336.70 million, with the most recent change of +$100.10 million (+42.31%) on 31 December 2023. During the last 3 years, it has risen by +$188.60 million (+127.35%). NBIX annual EBITDA is now at all-time high.NBIX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$191.30 M
+$35.70 M+22.94%
30 September 2024
Summary:
Neurocrine Biosciences quarterly earnings before interest, taxes, depreciation & amortization is currently $191.30 million, with the most recent change of +$35.70 million (+22.94%) on 30 September 2024. Over the past year, it has increased by +$44.60 million (+30.40%). NBIX quarterly EBITDA is now at all-time high.NBIX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$575.30 M
+$44.60 M+8.40%
30 September 2024
Summary:
Neurocrine Biosciences TTM earnings before interest, taxes, depreciation & amortization is currently $575.30 million, with the most recent change of +$44.60 million (+8.40%) on 30 September 2024. Over the past year, it has increased by +$275.70 million (+92.02%). NBIX TTM EBITDA is now at all-time high.NBIX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.3% | +30.4% | +92.0% |
| 3 y3 years | +127.3% | +379.4% | +196.6% |
| 5 y5 years | +498.1% | +179.7% | +787.1% |
NBIX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +143.8% | at high | +296.8% | at high | +1156.1% |
| 5 y | 5 years | at high | +498.1% | at high | +296.8% | at high | +1156.1% |
| alltime | all time | at high | +266.0% | at high | +251.3% | at high | +369.9% |
Neurocrine Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $191.30 M(+22.9%) | $575.30 M(+8.4%) |
| June 2024 | - | $155.60 M(+19.2%) | $530.70 M(+5.8%) |
| Mar 2024 | - | $130.50 M(+33.3%) | $501.80 M(+83.1%) |
| Dec 2023 | $336.70 M(+42.3%) | $97.90 M(-33.3%) | $274.10 M(-8.5%) |
| Sept 2023 | - | $146.70 M(+15.8%) | $299.60 M(+17.0%) |
| June 2023 | - | $126.70 M(-230.3%) | $256.00 M(+128.4%) |
| Mar 2023 | - | -$97.20 M(-178.8%) | $112.10 M(-52.6%) |
| Dec 2022 | $236.60 M(+71.3%) | $123.40 M(+19.7%) | $236.60 M(+117.1%) |
| Sept 2022 | - | $103.10 M(-699.4%) | $109.00 M(+138.0%) |
| June 2022 | - | -$17.20 M(-163.0%) | $45.80 M(-64.6%) |
| Mar 2022 | - | $27.30 M(-750.0%) | $129.30 M(-6.4%) |
| Dec 2021 | $138.10 M(-6.8%) | -$4.20 M(-110.5%) | $138.10 M(-28.8%) |
| Sept 2021 | - | $39.90 M(-39.8%) | $194.00 M(+80.1%) |
| June 2021 | - | $66.30 M(+83.7%) | $107.70 M(-20.2%) |
| Mar 2021 | - | $36.10 M(-30.2%) | $135.00 M(-8.8%) |
| Dec 2020 | $148.10 M(+72.4%) | $51.70 M(-211.4%) | $148.10 M(+2.0%) |
| Sept 2020 | - | -$46.40 M(-149.6%) | $145.20 M(-44.2%) |
| June 2020 | - | $93.60 M(+90.2%) | $260.00 M(+13.9%) |
| Mar 2020 | - | $49.20 M(+0.8%) | $228.20 M(+165.7%) |
| Dec 2019 | $85.90 M(+52.6%) | $48.80 M(-28.7%) | $85.90 M(+32.5%) |
| Sept 2019 | - | $68.40 M(+10.7%) | $64.85 M(+15.9%) |
| June 2019 | - | $61.80 M(-166.4%) | $55.97 M(-1810.5%) |
| Mar 2019 | - | -$93.10 M(-435.5%) | -$3.27 M(-105.8%) |
| Dec 2018 | $56.30 M(-146.7%) | $27.75 M(-53.4%) | $56.30 M(+29.2%) |
| Sept 2018 | - | $59.52 M(+2223.9%) | $43.57 M(-327.9%) |
| June 2018 | - | $2.56 M(-107.6%) | -$19.12 M(-74.9%) |
| Mar 2018 | - | -$33.53 M(-323.2%) | -$76.31 M(-36.7%) |
| Dec 2017 | -$120.62 M(-13.6%) | $15.02 M(-573.5%) | -$120.62 M(-32.9%) |
| Sept 2017 | - | -$3.17 M(-94.2%) | -$179.85 M(-15.6%) |
| June 2017 | - | -$54.63 M(-29.8%) | -$213.16 M(+7.4%) |
| Mar 2017 | - | -$77.84 M(+76.0%) | -$198.49 M(+40.5%) |
| Dec 2016 | -$139.64 M(+58.8%) | -$44.21 M(+21.2%) | -$141.23 M(+15.6%) |
| Sept 2016 | - | -$36.48 M(-8.7%) | -$122.22 M(+0.7%) |
| June 2016 | - | -$39.96 M(+94.1%) | -$121.34 M(+14.0%) |
| Mar 2016 | - | -$20.58 M(-18.3%) | -$106.46 M(+21.1%) |
| Dec 2015 | -$87.92 M(+38.3%) | -$25.20 M(-29.2%) | -$87.92 M(+6.0%) |
| Sept 2015 | - | -$35.60 M(+42.0%) | -$82.96 M(+29.6%) |
| June 2015 | - | -$25.07 M(+1126.6%) | -$64.00 M(+20.6%) |
| Mar 2015 | - | -$2.04 M(-89.9%) | -$53.08 M(-16.5%) |
| Dec 2014 | -$63.58 M(+29.7%) | -$20.24 M(+21.7%) | -$63.58 M(+16.2%) |
| Sept 2014 | - | -$16.64 M(+17.6%) | -$54.71 M(+9.6%) |
| June 2014 | - | -$14.15 M(+12.8%) | -$49.91 M(+2.4%) |
| Mar 2014 | - | -$12.55 M(+10.3%) | -$48.75 M(-0.5%) |
| Dec 2013 | -$49.01 M(-2428.1%) | -$11.37 M(-3.9%) | -$49.01 M(+69.7%) |
| Sept 2013 | - | -$11.84 M(-8.9%) | -$28.88 M(+38.6%) |
| June 2013 | - | -$12.99 M(+1.5%) | -$20.84 M(+130.1%) |
| Mar 2013 | - | -$12.80 M(-246.2%) | -$9.05 M(-530.2%) |
| Dec 2012 | $2.10 M(-93.9%) | $8.76 M(-330.5%) | $2.10 M(-134.7%) |
| Sept 2012 | - | -$3.80 M(+212.9%) | -$6.06 M(-121.4%) |
| June 2012 | - | -$1.21 M(-26.0%) | $28.31 M(-8.1%) |
| Mar 2012 | - | -$1.64 M(-378.4%) | $30.80 M(-11.0%) |
| Dec 2011 | $34.62 M(-381.8%) | $589.00 K(-98.1%) | $34.62 M(+1.2%) |
| Sept 2011 | - | $30.58 M(+2307.7%) | $34.20 M(+431.6%) |
| June 2011 | - | $1.27 M(-41.7%) | $6.43 M(-1857.9%) |
| Mar 2011 | - | $2.18 M(+1138.1%) | -$366.00 K(-97.0%) |
| Dec 2010 | -$12.29 M | $176.00 K(-93.7%) | -$12.29 M(-49.2%) |
| Sept 2010 | - | $2.81 M(-150.8%) | -$24.17 M(-32.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$5.53 M(-43.2%) | -$35.86 M(-19.1%) |
| Mar 2010 | - | -$9.74 M(-16.8%) | -$44.35 M(-7.5%) |
| Dec 2009 | -$47.93 M(-35.2%) | -$11.71 M(+32.0%) | -$47.93 M(-19.6%) |
| Sept 2009 | - | -$8.88 M(-36.7%) | -$59.66 M(-7.5%) |
| June 2009 | - | -$14.02 M(+5.2%) | -$64.51 M(-6.0%) |
| Mar 2009 | - | -$13.33 M(-43.1%) | -$68.61 M(-7.3%) |
| Dec 2008 | -$73.98 M(-63.5%) | -$23.43 M(+70.6%) | -$73.98 M(-58.2%) |
| Sept 2008 | - | -$13.73 M(-24.2%) | -$176.97 M(-6.8%) |
| June 2008 | - | -$18.12 M(-3.1%) | -$189.85 M(-3.5%) |
| Mar 2008 | - | -$18.70 M(-85.2%) | -$196.82 M(-3.0%) |
| Dec 2007 | -$202.84 M(+97.4%) | -$126.43 M(+375.0%) | -$202.84 M(+125.1%) |
| Sept 2007 | - | -$26.61 M(+6.1%) | -$90.09 M(-10.8%) |
| June 2007 | - | -$25.08 M(+1.5%) | -$101.04 M(-1.5%) |
| Mar 2007 | - | -$24.71 M(+80.6%) | -$102.54 M(-0.2%) |
| Dec 2006 | -$102.75 M(+586.0%) | -$13.68 M(-63.6%) | -$102.75 M(-7.5%) |
| Sept 2006 | - | -$37.56 M(+41.4%) | -$111.06 M(+142.3%) |
| June 2006 | - | -$26.57 M(+6.6%) | -$45.83 M(+99.2%) |
| Mar 2006 | - | -$24.93 M(+13.4%) | -$23.00 M(+53.6%) |
| Dec 2005 | -$14.98 M(-66.9%) | -$21.99 M(-179.5%) | -$14.98 M(+25.9%) |
| Sept 2005 | - | $27.66 M(-838.3%) | -$11.89 M(-70.6%) |
| June 2005 | - | -$3.75 M(-77.8%) | -$40.50 M(-16.8%) |
| Mar 2005 | - | -$16.91 M(-10.6%) | -$48.67 M(+7.6%) |
| Dec 2004 | -$45.25 M(-17.9%) | -$18.91 M(+1913.4%) | -$45.25 M(+5.4%) |
| Sept 2004 | - | -$939.00 K(-92.1%) | -$42.92 M(-21.3%) |
| June 2004 | - | -$11.92 M(-11.6%) | -$54.54 M(+0.8%) |
| Mar 2004 | - | -$13.49 M(-18.6%) | -$54.10 M(-1.8%) |
| Dec 2003 | -$55.09 M(-45.2%) | -$16.57 M(+32.0%) | -$55.09 M(-30.2%) |
| Sept 2003 | - | -$12.56 M(+9.4%) | -$78.89 M(-10.4%) |
| June 2003 | - | -$11.48 M(-20.7%) | -$88.05 M(-10.0%) |
| Mar 2003 | - | -$14.49 M(-64.1%) | -$97.88 M(-2.6%) |
| Dec 2002 | -$100.52 M(+143.8%) | -$40.36 M(+85.9%) | -$100.52 M(+34.3%) |
| Sept 2002 | - | -$21.72 M(+1.9%) | -$74.83 M(+46.1%) |
| June 2002 | - | -$21.32 M(+24.5%) | -$51.23 M(+14.2%) |
| Mar 2002 | - | -$17.12 M(+16.7%) | -$44.87 M(+8.8%) |
| Dec 2001 | -$41.23 M(+23.4%) | -$14.67 M(-880.4%) | -$41.23 M(+10.6%) |
| Sept 2001 | - | $1.88 M(-112.6%) | -$37.29 M(-22.8%) |
| June 2001 | - | -$14.95 M(+10.9%) | -$48.29 M(+20.2%) |
| Mar 2001 | - | -$13.49 M(+25.7%) | -$40.18 M(+20.3%) |
| Dec 2000 | -$33.40 M(+87.7%) | -$10.73 M(+17.6%) | -$33.40 M(+23.4%) |
| Sept 2000 | - | -$9.12 M(+33.3%) | -$27.07 M(+20.6%) |
| June 2000 | - | -$6.84 M(+2.0%) | -$22.45 M(+9.5%) |
| Mar 2000 | - | -$6.71 M(+52.4%) | -$20.50 M(+15.9%) |
| Dec 1999 | -$17.80 M(+66.4%) | -$4.40 M(-2.2%) | -$17.69 M(+6.6%) |
| Sept 1999 | - | -$4.50 M(-8.0%) | -$16.59 M(+12.9%) |
| June 1999 | - | -$4.89 M(+25.4%) | -$14.69 M(+14.8%) |
| Mar 1999 | - | -$3.90 M(+18.2%) | -$12.80 M(+17.4%) |
| Dec 1998 | -$10.70 M(-694.4%) | -$3.30 M(+26.9%) | -$10.90 M(+28.2%) |
| Sept 1998 | - | -$2.60 M(-13.3%) | -$8.50 M(+41.7%) |
| June 1998 | - | -$3.00 M(+50.0%) | -$6.00 M(+71.4%) |
| Mar 1998 | - | -$2.00 M(+122.2%) | -$3.50 M(-284.2%) |
| Dec 1997 | $1.80 M(-53.8%) | -$900.00 K(+800.0%) | $1.90 M(-70.3%) |
| Sept 1997 | - | -$100.00 K(-80.0%) | $6.40 M(+20.8%) |
| June 1997 | - | -$500.00 K(-114.7%) | $5.30 M(-27.4%) |
| Mar 1997 | - | $3.40 M(-5.6%) | $7.30 M(+87.2%) |
| Dec 1996 | $3.90 M | $3.60 M(-400.0%) | $3.90 M(+1200.0%) |
| Sept 1996 | - | -$1.20 M(-180.0%) | $300.00 K(-80.0%) |
| June 1996 | - | $1.50 M(>+9900.0%) | $1.50 M(>+9900.0%) |
| Mar 1996 | - | $0.00 | $0.00 |
FAQ
- What is Neurocrine Biosciences annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual EBITDA year-on-year change?
- What is Neurocrine Biosciences quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly EBITDA year-on-year change?
- What is Neurocrine Biosciences TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM EBITDA year-on-year change?
What is Neurocrine Biosciences annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NBIX is $336.70 M
What is the all time high annual EBITDA for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual earnings before interest, taxes, depreciation & amortization is $336.70 M
What is Neurocrine Biosciences annual EBITDA year-on-year change?
Over the past year, NBIX annual earnings before interest, taxes, depreciation & amortization has changed by +$100.10 M (+42.31%)
What is Neurocrine Biosciences quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NBIX is $191.30 M
What is the all time high quarterly EBITDA for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly earnings before interest, taxes, depreciation & amortization is $191.30 M
What is Neurocrine Biosciences quarterly EBITDA year-on-year change?
Over the past year, NBIX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$44.60 M (+30.40%)
What is Neurocrine Biosciences TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NBIX is $575.30 M
What is the all time high TTM EBITDA for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM earnings before interest, taxes, depreciation & amortization is $575.30 M
What is Neurocrine Biosciences TTM EBITDA year-on-year change?
Over the past year, NBIX TTM earnings before interest, taxes, depreciation & amortization has changed by +$275.70 M (+92.02%)